Let us be honest

Total Rating:
0 / 0

1 Comment

    • Tue Jan 22nd 12:40 PM | Rating: 0 0
      Commented on:
      Elan, Biogen Idec Won't Gain Much from Tysabri Approval
      It is sad and pathetic and infuriating that the people who affect financial markets do their research like C-grade students. I am not trying to have a personal attack at Dr. Dave (by the way, the "Dr." of what?) but I think such "experts" should have some responsibility for their writings if it may affect markets and companies that they know very very little about. Of course the markets are rarely driven by cold analysis of the facts but rather by speculation, greed, fear and rumors. However there is still no excuse to write ignorant and blatantly wrong pieces like the one above just in order to churn up the volume of these writing and justify some unreasonably high salaries of financial "analysts".....

      Enbrel, Remicade and Humira are all drugs that belong to the class of TNF inhibitors. These drugs are used to treat inflammation caused by autoimmune diseases. Though Tysabri "targets" a completely different target (α4-subunit of α4β1 and α4β7 integrins) and thus has a very different mechanism of action it is also used to treat autoimmune diseases.

      Doctors treat autoimmune diseases by reducing the activity of a patient's immune system that obviously makes them more susceptible to infections (viral, like PML, or bacterial) or possibly even some forms of cancer. Enbrel, Remicade, and Humira are very efficient treatments of autoimmune diseases and also generate several Billions of Dollars in sales. These therapies also are a classic story of a risk-benefit analysis. The enormous benefit of the use of TNF inhibitors has proven that the risk of the side effects due to the weakened immune system is completely justified by the improvements in the Quality of Life and the extremely low frequency of dangerous side effects. Tysabri is yet another novel and remarkably efficient autoimmune drug that has brought the relief to many many MS sufferers. When Tysabri was temporarily withdrawn from the market due to the safety concerns many patients and numerous patient-advocacy groups petitioned the FDA and BiogenIdec and Elan to bring it back to the market.

      The others ahead of me already pointed out that a single therapy Tysabri was not associated with PML and I will not go there again. Those who are concerned about drug side effects and their 100% safety look at cancer drugs (no comment). Moreover, check the research that was done on Tylenol and its side effects (don't do it at night - it is too scary). My advice to those who expect to ever use drugs, "strong or week", that would have Zero side effects and the Maximum efficacy - just don't get sick since you will have left only water for your treatment(and it also should be used in moderation please). So, when you research a product or a company please do not rely on the writing of the people who have the unjustified influence on markets (albeit not for a long time) do the research yourself and check the multiple sources of the information.
      View article »
Loading...
Symbols:
Authors:
Quick Links:
Contribute an Article Become a Seeking Alpha Contributor

Transcripts

More Transcripts»